Chemotherapy Induced Nausea And Vomiting Treatment Market

Chemotherapy Induced Nausea and Vomiting Treatment Market Outlook (2024 to 2034)

The global Chemotherapy Induced Nausea and Vomiting Treatment Market was valued at around US$ 6,412.0 million at the end of 2023. The market is projected to register a 6.4% CAGR and top a valuation of US$ 12,688.0 Million by 2034.

CINV market dynamics are mainly driven by the increasing prevalence of cancer in large populations of the world. Chemotherapy, being amongst the key cancer treatments, has several side effects, nausea and vomiting being one of them, that are difficult to tolerate for the patient. With a progressively increasing pool of patients afflicted with cancer, the number of patients opting for chemotherapy treatment would also increase correspondingly.

The unproblematic and easy access to strong medications purely designed for the treatment of chemotherapy-induced nausea and vomiting, along with significant development in the formulation techniques, a rise in the demand for combination therapies, and an increasing interest in novel methods for the improvement of the overall quality of life in cancer patients are driving the unprecedented growth of the market related to the treatment of CINV.

Ondensetron and Granisetron (5-HT3 receptor antagonists) are most commonly used for the treatment. Aprepitants and rolapritants are the type of Neurokinin-1 (NK-1) receptor antagonists used in combination with serotonin receptor antagonists. Apart from this corticosteroids and cannabinoid receptor agonists are used in CINV treatment.

Report Attributes	Details
Chemotherapy Induced Nausea and Vomiting Treatment Market Size (2023A)	US$ 6,412.0 Million
Estimated Market Value (2024E)	US$ 6,823.0 Million
Forecasted Market Value (2034F)	US$ 12,688.0 Million
Global Market Growth Rate (2024-2034)	6.4% CAGR
Western Europe Market Share (2024)	6.0%
U.K. Market Growth Rate (2024-2034)	6.2% CAGR
Key Companies Profiled	Kyowa Kirin, Inc.; Pfizer Inc.; GlaxoSmithKline plc.; AbbVie Inc. (Allergan plc); Merck & Co., Inc.; Bausch Health Companies Inc.; Novartis AG; Ono Pharmaceutical Co., Ltd.; Camurus AB; Heron Therapeutics, Inc.

Historic Analysis (2019 to 2023) and Future (2024 to 2034) Pathway Analysis for the Chemotherapy Induced Nausea and Vomiting Treatment Market

The historic growth rate for CINV treatment market from 2019 to 2023 was 4.9% and by the end of 2023, it was valued at US$ 6,412.0 million. The wide adoption of 5-HT3 antagonists and NK-1 receptor antagonists was observed with combination of other treatments in the historic period 2019-2023.

Historical Report Attributes	Details
Market Size (2019A)	US$ 5,289.0 million
Market Size (2023A)	US$ 6,412.0 million
Historical CAGR (2019-2023)	4.9%
Forecasted CAGR (2024-2034)	6.4%

• Short Term (2024 to 2028): North America and Western Europe will be the dominant market in this period because of ongoing treatment research and emergence of next generation antiemetics with fewer side effects. The rising patient awareness, expanding healthcare infrastructure and increasing number of cancer patients are the primary drivers in emerging economies. The personalized treatment options based on genetic data, use of novel drug delivery systems are also expected to gain more attraction in this period.
• Medium Term (2028 to 2030): In the developed regions such as North America and Europe market may become saturated which can stabilize the growth at maturity level in these regions. The continuous innovation in precision oncology will continue the demand for CINV treatment market. The Asia-pacific region will emerge as key growth region in this time frame.
• Long Term (2030 to 2034): In this period the use of advanced therapies such as CRISPER, gene therapy, and other precision medicines will evolve in CINV treatment market. The development of novel biologics and biosimilars with long lasting and more effective actions may observed in this future era. North America and Western Europe will continue to dominate the market and Asia-Pacific will experience the promising growth.

Market Dynamics

What are the Factors Propelling Global Chemotherapy Induced Nausea and Vomiting Treatment Market?

“Worldwide Increase in the Incidence of Cancer is driving the Demand for Chemotherapy Induced Nausea and Vomiting Treatment Market”

An estimated 20 million new cases of cancer and 9.7 million deaths from cancer occurred in 2022. In 2050, estimates by the WHO are over 35 million new cases of cancer. It represents a 77% increase over 2022. Increased cancer incidence is ultimately rising the number of patients undergoing chemotherapy. Nausea and vomiting are the most common side effects of chemotherapy medications which can affect majorly to patient’s quality of life. Hence, it is very crucial to manage CINV.

The heavy investment in research and development has been done by pharmaceutical companies for the manufacturing of anti-emetic drugs with improved action. The combination drugs are being developed to provide the long lasting effect and improve patient outcomes.

In developed regions like North America and Western Europe the emphasis on better quality of life and patient care is on priority which is responsible for adoption of novel therapies in these regions. Also, these regions have well developed healthcare infrastructure and they are more prevalent to the cancer. Hence, these regions ae dominating the CINV treatment market. On the other hand, in the developing regions like Asia-pacific, Latin America, and Africa cancer incidence rates are being observed to increase rapidly. These developing regions are also experiencing significant growth in CINV treatment market.

“Advancements in Anti-emetic Therapies”

In recent decades, scientists have put more effort into figuring out how CINV works. For instance, doctors can now use aprepitant (an NK-1 receptor blocker) along with other anti-nausea drugs such as serotonin blockers and steroids. Another big step forward is the green light given to Akynzeo, a single tablet that has both palonosetron (a 5-HT3 receptor blocker) and netupitant (an NK-1 receptor blocker) in it.

Various drug delivery methods play a role in treating CINV. Other ways to give medicine, like long-lasting shots and skin patches, are becoming more popular for making anti-nausea drugs. For example, Cumberland Pharmaceuticals created Sancuso (a granisetron skin patch). This patch is the first and one doctors can prescribe to prevent CINV.

What are the Factors Restraining Chemotherapy Induced Nausea and Vomiting Treatment Market?

Even after the extensive study and formulation of antiemetic drugs it is challenging to treat CINV. Poor management can lead to the significant financial burden and it can impact standard of living. Various unmet needs are necessary to address the non-acute CINV and developing accurate and suitable treatment protocols for patients undergoing chemotherapy.

The cost concern is one of the major factors. The cost of advanced drugs such as Nk-1 receptors for ex. fosaprepitant and aprepitant can be high and can cost upto several hundred dollars per dose. Also, these medications are used in combination with other antiemetic drug classes which ultimately rises the total cost of the treatment. The low and middle income countries are get majorly affected by this financial burden due to constrained healthcare budgets.

In publicly funded healthcare systems the healthcare practitioners found reluctant to prescribe such high cost drugs due to financial limitations. Furthermore, the stringent regulatory laws associated with cancer drugs are complicated in North America and Europe. The market for CINV treatment in U.S., U.K., and some countries of Europe is predicted to decline because of stringent regulations and loss of exclusivity of several generic medicines.

Some of the anti-emetic drugs used for CINV management such as serotonin antagonists (ondansetron and granisetron) are linked with side effects such as constipation, headaches, and fatigue. These side effects are not major and manageable. However, they can affect significantly to the patients undergoing multiple chemotherapy cycles. Similarly, NK-1 receptos antagonists can cause dizziness, hiccups, and fatigue while corticosteroids such as dexamethasone is associated with risen blood sugar level, mood changes, and insomnia. The severity of these side effects can be responsible for non-adherence of patients to prescribed antiemetic treatment protocol.

Country-wise Insights

How Lucrative is the Opportunity for Chemotherapy Induced Nausea and Vomiting drugs Manufacturers in the U.S.?

United States Chemotherapy Induced Nausea and Vomiting Treatment Market is estimated at US$ 2,475.9 million in 2024 and is projected to expand at a CAGR of 6.0% through 2034.

Approximately 1.9 million new cases arises annually in U.S. for cancer. Chemotherapy is vital treatment in the treatment of cancer. The high incidence of cancer increases the number of patients undergoing chemotherapy and so as it need effective management of associated CINV. U.S. has strong healthcare system which invests heavily in cancer treatment and significant portion of this investment is being used in the management of side effects associated with cancer therapy.

The manufacturers in the U.S. market are focusing on development of drugs treating CINV with minimal side effects. For this purpose the innovation, research and development is on surge and the various combination drugs are being approved in the U.S. for CINV treatment. For instance, in November 2017, USFDA approved Cinvanti (aprepitant) manufactured by Heron Therapeutics which can be used with serotonin antagonists in combination. Thus, increased incidence of cancer, high R&D investment and robust healthcare infrastructure is providing opportunities for effective management of CINV.

How Increased Focus on Maintaining Superior Quality of Life Impacts Growth Of Chemotherapy Induced Nausea And Vomiting Treatment Market in the U.K?

U.K. accounted for 21.3% of market share in Western Europe CINV treatment market. The market value for U.K. CINV treatment market was estimated to be US$ 275.0 million in 2024 and it is expected to reach US$ 503.0 million at the end of 2034 with CAGR of 6.2%.

High per capita healthcare expenditure favorable reimbursement policies, well established healthcare facilities, and increased number of patients undergoing chemotherapy are the primary drivers responsible for high growth of CINV treatment market in United Kingdom.

Why there is a Surge in Adoption of Chemotherapy-Induced Nausea and Vomiting Treatment in China?

The increased aging population, changes in lifestyle, and environmental factors have resulted in the increased number of cancer cases in China. In 2024 the China’s CINV treatment market was valued at US$ 355.9 million and is expected to register growth rate of 8.2%.

Increased patient awareness, high expectations for effective management of cancer, government initiatives, reimbursement policies, rising disposable income, expanding middle class and entry of international as well as domestic pharmaceutical companies in market are driving CINV treatment market in China.

Category-wise Insights

Which Drug Type is expected to Grow Rapidly in the Chemotherapy Induced Nausea and Vomiting Treatment Market?

“Superior Efficacy of NK-1 Receptor Antagonists in preventing both Acute and Delayed CINV is driving its Market Growth”

Demand for NK-1 receptor antagonists is projected to increase from US$ 2,173.2 million to US$ 3,997.7 million at a CAGR of 6.3% from 2024 to 2034. Both the delayed and acute forms of CINV respond to treatment with NK-1 receptor antagonists. NK-1 receptor antagonists have a more powerful effect when combined with other anti-nausea drugs.

For example, Merck's Emend (aprepitant) works well with 5-HT3 receptor antagonists and corticosteroids to treat delayed CINV. New versions of NK-1 receptor antagonists help cut down on side effects. Civanti by Heron Therapeutics, for instance, doesn't have polysorbate 80 in its injectable form, which makes allergic reactions less likely.

Why is Demand for 5-HT3 Receptor Antagonists on the Rise?

5-HT3 antagonists (serotonin antagonists) estimated to have highest market share of 44.1% in 2024 and it is expected to reach at the valuation of US$ 6,099.0 million in 2034 with the incremental opportunity of US$ 3,089.4 million in between 2024-2034. The 5-HT3 receptor antagonists is effective in treatment of acute CINV. It is the most prescribed anti-emetic drug class and it has broad use in combination therapies.

The longer acting formulations of 5-HT3 antagonists are being developed in the market for expanding its action including delayed CINV. The easy availability of generic form of serotonin antagonists has resulted in higher growth of this drug class in CINV market due to its cost effectiveness.

Competitive Landscape

Key players in the Chemotherapy Induced Nausea and Vomiting Treatment market are Kyowa Kirin, Inc., Pfizer Inc., GlaxoSmithKline plc., AbbVie Inc. (Allergan plc), Merck & Co., Inc., Bausch Health Companies Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Camurus AB, and Heron Therapeutics, Inc.

Companies are focusing on innovations, expanding geographical reach, and strategic partnerships with other market players to retain and increase their market share.

Segmentation of Chemotherapy Induced Nausea and Vomiting Treatment Industry Research

• By Drugs Type :

  • 5-HT3 Receptor Antagonists
  • Neurokinin-1 Receptor Antagonists
  • Corticosteroids
  • Cannabinoid Receptor Agonist
  • Others

• By Emetogenic Risk :

  • Highly Emetogenic Chemotherapy (HEC)
  • Moderately Emetogenic Chemotherapy (MEC)
  • Low Emetogenic Chemotherapy (LEC)

• By Form :

  • Injectable
  • Oral
  • Transdermal Patches

• By Distribution Channel :

  • Hospitals
  • Cancer Research Institutes
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa